Browse our latest Microbiology and Infectious Disease articles

The development of new small molecules demonstrates how pharmacologic inhibition of the coronavirus macrodomain restores innate immunity, leading to reduced viral replication and improved outcomes in severe infection.

Unraveling mechanisms underlying post-acute SARS-CoV-2 sequelae (long COVID) and finding therapeutic solutions require a full understanding of the causative role of SARS-CoV-2 persistence and/or infection with other microorganisms, which may be pre-existing, concurrent, or subsequent to acute COVID-19.

Epigenetic and metabolic programming of innate immune cells shapes host defense and disease susceptibility.

Classical antibody boosting effects during vaccination are accompanied by natural broadening mechanisms that help enable human antibodies to engage conserved sites of vulnerability on influenza virus.

Our latest Focus Issue looks at what we’ve learnt over the past decade and what’s next for the field of trained immunity.

The articles in this focus issue discuss progress towards a more complete understanding of memory in the innate immune system, and efforts to exploit "trained immunity" for the development of new vaccines and therapeutics.

The pathogenic bacteria Shigella avoids detection inside hosts cells by degrading RNF213, the protein responsible for sensing the presence of intracellular pathogens.

Routine genomic surveillance uncovered a decades-long multidrug-resistant Pseudomonas aeruginosa outbreak sustained by patient reservoirs and hospital plumbing, enabling targeted infection control measures that ultimately curtailed transmission.

Intermolecular steric repulsion generated by glycans on the cell membrane inhibits viral infection by preventing the formation of a virus-cell interface, regardless of the identity of molecules for glycan modification.

Evolutionary changes in RNA binding and antiviral activity result in diverse IFIT1 functions across mammals, even among closely related species.